CLINICAL_TRIALS ClinicalTrials.gov record update

An Open-label, Single-center Study of Remibrutinib Using Ultra High-field (7T) MR Imaging in Relapsing or Progressive MS (RemiSeven)

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Record identity and dates

Source: ClinicalTrials.gov
Source record ID: NCT07222956
Title field or adapter rule: protocolSection.identificationModule.officialTitle
Ingested At: 2026-04-25T22:29:01.037931+00:00
Published At: 2025-10-30T00:00:00+00:00
Record Updated At: 2025-10-30
Timestamp Basis: source retrieval time was not retained by the feed adapter
Date limitation: source retrieval time was not retained by the feed adapter

protocolSection.conditionsModule.conditions: ["Multiple Sclerosis (MS) - Relapsing-remitting", "Multiple Sclerosis (MS) Secondary Progressive", "Multiple Sclerosis (MS) Primary Progressive"]
protocolSection.statusModule.lastUpdatePostDateStruct.date: "2025-10-30"
protocolSection.identificationModule.nctId: "NCT07222956"
protocolSection.identificationModule.officialTitle: "An Open-label, Single-center Study of Remibrutinib Using Ultra High-field (7T) MR Imaging in Relapsing or Progressive MS (RemiSeven)"
protocolSection.statusModule.overallStatus: "NOT_YET_RECRUITING"
protocolSection.designModule.phases: ["PHASE2"]
protocolSection.statusModule.resultsFirstPostDateStruct.date: ""

Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.